Effect of vonoprazan on gut microbiota in patients with gastroesophageal reflux disease (GERD)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066238

Enrollment

Unknown

Registered

2022-11-29

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease (GERD)

Interventions

Vonoprazan treatment group:vonoprazan

Esomeprazole treatment group:Esomeprazole

Healthy control group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Eligible GERD patients aged 18 to 75 years with reflux esophagitis confirmed by endoscopy (Los Angeles classification). Healthy control group: normal endoscopic findings, negative test for H. pylori infection (assessed using a 13C breath test), and no use of PPIs, P-CABs, or antibiotics within 6 months before study initiation.

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1. Allergy to any study drug; 2. Serious concomitant diseases, including heart disease, renal failure, liver disease, diabetes, etc. 3. Use of PPIs, P-CABs, antibiotics, probiotics, etc. in the past 6 months. 4. Lack of informed consent.

Design outcomes

Primary

Measure	Time frame
gut microbiota;	—

Countries

China

Contacts

Public ContactLv Tao

Hong Kong University Shenzhen Hospital

lvt@hku-szh.org18307556803

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026